Strategies adopted by men to deal with uncertainty and anxiety when following an active surveillance/monitoring protocol for localised prostate cancer and implications for care: a longitudinal qualitative study embedded within the ProtecT trial
Chris Metcalfe,
Jenny Donovan,
Julia Wade,
Vincent J Gnanapragasam,
Michael Davis,
David Neal,
Richard Martin,
Athene Lane,
Edward Rowe,
Freddie Hamdy,
James Catto,
Emma Turner,
David Gillatt,
Eleanor Walsh,
Derek Rosario,
Tim Peters,
Roger Kockelbergh,
Alan Paul,
Peter Holding,
Howard Kynaston,
Owen Hughes,
Prasad Bollina,
Alan Doherty,
Edgar Paez
Affiliations
Chris Metcalfe
1 Population Health Sciences, Bristol Medical School, Bristol, Bristol, UK
Jenny Donovan
Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
Julia Wade
Population Health Science, Bristol Medical School, University of Bristol, Bristol, UK
Vincent J Gnanapragasam
Department of Surgery, University of Cambridge, Cambridge, UK
Michael Davis
research associate in health services research
David Neal
Nuffield Department of Surgical Sciences, Oxford University, Oxford, UK
Richard Martin
MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK
Athene Lane
Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
Edward Rowe
6 Bristol Urology Institute, Department of Urology, North Bristol NHS Trust, Bristol, UK
Freddie Hamdy
Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK
James Catto
13 Academic Urology Unit, The University of Sheffield, Sheffield, UK
Emma Turner
Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
David Gillatt
MQ Health, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, New South Wales, Australia
Eleanor Walsh
1School of Social and Community Medicine, University of Bristol, Bristol, UK
Derek Rosario
Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK
Tim Peters
Population Health Sciences, University of Bristol, Bristol, UK
Roger Kockelbergh
Department of Urology, University Hospitals of Leicester NHS Trust, Leicester, UK
Alan Paul
Department of Urology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
Peter Holding
Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK
Howard Kynaston
School of Medicine, Cardiff University, Cardiff, UK
Owen Hughes
Department of Urology, Cardiff and Vale University Health Board, Cardiff, UK
Prasad Bollina
Department of Urology, NHS Lothian, Edinburgh, UK
Alan Doherty
Department of Urology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
Edgar Paez
Department of Urology, Newcastle Upon Tyne Hospitals NHS Trust, Newcastle Upon Tyne, UK
Objectives Active surveillance (AS) enables men with low risk, localised prostate cancer (PCa) to avoid radical treatment unless progression occurs; lack of reliable AS protocols to determine progression leaves uncertainties for men and clinicians. This study investigated men’s strategies for coping with the uncertainties of active monitoring (AM, a surveillance strategy within the Prostate testing for cancer and Treatment, ProtecT trial) over the longer term and implications for optimising supportive care.Design Longitudinal serial in-depth qualitative interviews every 2–3 years for a median 7 (range 6–14) years following diagnosis.Setting Four centres within the UK Protect trial.Participants Purposive sample of 20 men with localised PCa: median age at diagnosis 64 years (range 52–68); 15 (75%) had low-risk PCa; 12 randomly allocated to, 8 choosing AM. Eleven men continued with AM throughout the study period (median 7 years). Nine received radical treatment after a median 4 years (range 0.8–13.8 years).Intervention AM: 3-monthly serum prostate-specific antigen (PSA)-level assessment (year 1), 6–12 monthly thereafter; increase in PSA ≥50% during previous 12 months or patient/clinician concern triggered review.Main outcomes Thematic analysis of 73 interviews identified strategies to accommodate uncertainty and anxiety of living with untreated cancer; implications for patient care.Results Men sought clarity, control or reassurance, with contextual factors mediating individual responses. Trust in the clinical team was critical for men in balancing anxiety and facilitating successful management change/continued monitoring. Only men from ProtecT were included; men outside ProtecT may have different experiences.Conclusion Men looked to clinicians for clarity, control and reassurance. Where provided, men felt comfortable continuing AM or having radical treatments when indicated. Clinicians build patient trust by clearly describing uncertainties, allowing patients control wherever possible and being aware of how context influences individual responses. Insights indicate need for supportive services to build trust and patient engagement over the long term.Trial registration number ISRCTN20141297; Pre-results.